JADPRO Live

Using gender-neutral language is the first step in making a safe space for LGBTQIA+ patients with cancer, explained Al Asante-Facey, PA, MBA.

Paola Gonzalez, MPAS, PA-C, explains how third-party vendors shape insurance guidelines and what oncology APPs should know when navigating peer-to-peer reviews.

Dermatitis and lymphedema are among the most pertinent adverse effects of radiation to the breast, according to Alexa M. Lantz, MSPAS, PA-C.

Kevin Y. Chen, PharmD, MS, BCOP, CPP, discusses how next-generation sequencing improves biomarker testing and treatment planning in solid tumors.

A patient with breast cancer and generalized anxiety disorder was able to avoid an unnecessary mastectomy with virtual reality, said Kelly Preti, DNP.

A multisite advanced practice optimization model improved patient access through tailored interventions, including redistributing non-APP responsibilities.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, discusses the growing number of new therapies for patients with relapsed or refractory multiple myeloma.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Kristin Daly, MSN, ANP-BC, AOCNP, explains how providers approach staging and treatment decision-making in head and neck cancer.

Leah Shaw, MSN, APRN, AGPCNP-BC; and Jessica Deinert, MSN, APRN, FNP-BC, share their clinical pearls in managing treatment-related adverse events in prostate cancer care.

Stephanie L. Graff, MD, FACP; Christine McGinn, MSN, APRN, ACNP-BC; and Jeanine Showalter, MSN, APRN, FNP-BC, AOCNP, share how they approach treatment decision-making following a brain metastasis.

Beth Sandy, MSN, CRNP, and Tajuana Bradley, MSN, APRN-BC, discuss the importance of molecular testing in non–small cell lung cancer.

Tammy Triglianos, DNP, ANP-BC, AOCNP, discusses optimal adjuvant treatment approaches for patients with stage III colon cancer.